Skip to main content

Omnicell Value Stock - Dividend - Research Selection

Omnicell

ISIN: US68213N1090 , WKN: 632313

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Robotics Earnings Week: Momentum vs. Value as Four Automation Names Report

2026-09-25
Robotics automation earnings preview: Teradyne, Cognex, Omnicell, UiPath face key tests as momentum leaders and value laggards report.

Omnicell (OMCL) Stock Trades Below Fair Value After A 78% Slump

2026-09-22
Omnicell trades around US$33.17 after a mixed share price record, and the key issue now is whether that level lines up with the cash the business can generate over time. With the stock showing both long slumps and shorter rebounds, investors are left asking how closely the current market value tracks the company’s underlying cash flows. Over the past 5 years the share price has fallen 77.7%, which puts the spotlight firmly on whether the long term cash flow potential still supports today’s...

3 Reasons OMCL is Risky and 1 Stock to Buy Instead

2026-09-21
Omnicell has been treading water for the past six months, recording a small loss of 4.6% while holding steady at $32.74. The stock also fell short of the S&P 500’s 16.4% gain during that period.

Strength Seen in Tempus (TEM): Can Its 14.9% Jump Turn into More Strength?

2026-09-18
Tempus (TEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

1 Cash-Heavy Stock to Target This Week and 2 We Question

2026-09-11
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

1 Cash-Producing Stock on Our Buy List and 2 We Ignore

2026-09-10
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

2026-09-03
TraceLink, the world's largest Agentic Business Network for the life sciences and healthcare supply chain, today announced an integration between its Drug Supply Chain Security Act (DSCSA) compliance solution and the pharmacy inventory management systems of Omnicell, Inc. (Nasdaq: OMCL), a leading healthcare technology provider focused on empowering autonomous medication management. This integration is expected to enable hospitals and health systems to manage product verification, traceability,

Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

2026-08-31
FORT WORTH, Texas, August 31, 2026--Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

Three Earnings Reports Put the Automation Rally to the Test

2026-08-27
Three robotics earnings reports from Cognex, Omnicell, and UiPath test whether the automation rally is fundamentals-driven or just momentum.

Omnicell: Offers Good Value, But Uncertainty Remains

2026-08-25
Omnicell, Inc. is rated a Hold; it faces near-term headwinds, with YoY revenue contraction, for the first time in seven quarters. Read more on OMCL stock here.